Skip to content

Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul

Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055)

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00947362
Acronym
rtt-ACL
Enrollment
134
Registered
2009-07-28
Start date
2004-08-01
Completion date
2007-12-15
Last updated
2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound Healing

Brief summary

The aim of the randomized double blind trial with 134 patients presenting old world cutaneous leishmaniasis is: * to evaluate the clinical efficacy of electro-thermo-cauterisation (ETC) followed by moist wound treatment versus ETC followed by moist wound treatment plus 0.05 % pharmaceutical chlorite that has been used in three European countries (Germany, Austria and Switzerland) in wound care management for more than 20 years; * to judge whether early wound care management would present a viable improvement to the actual anti-parasitic treatments mostly neglecting the chronic wound problem and to evaluate its long-term effect on immunity through relapse control 6 months after wound healing.

Interventions

moist wound treatment plus 0.05 % pharmaceutical chlorite

DRUGsaline

physiological saline

Sponsors

German Medical Service (GMS) in Kabul
CollaboratorOTHER
University of Freiburg
CollaboratorOTHER
Waisenmedizin e. V. Promoting Access to Essential Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
5 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* at least one suspected lesion positive in Giemsa smear

Exclusion criteria

* patients previously treated for leishmania

Design outcomes

Primary

MeasureTime frameDescription
Days for wound closureFrom the day of treatment start to the day of wound closureDays for primary wound closure

Secondary

MeasureTime frameDescription
Leishmania parasites load per gram of tissue before and after treatmentBefore treatment start and at day wound closureParasite load per gram of tissue

Countries

Afghanistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026